Trial Profile

Phase IIb trial of EVT-201 for treatment of insomnia in China

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dimdazenil (Primary)
Indications Insomnia
Focus Therapeutic Use
Sponsors Zhejiang Jingxin Pharmaceutical

Most Recent Events

14 Mar 2015 Status changed from not yet recruiting to recruiting in 2014, according to an Evotec media release.
12 Aug 2014 According to an Evotec media release, JingXin Pharmaceutical Co., Ltd, received approval from the China State Food and Drug Administration (SFDA) for this study and plans to start in the second half of 2014.
09 Aug 2013 According to an Evotec media release, Zhejiang JingXin Pharmaceutical was granted permission in April 2013 by the Chinese Center of Drug Evaluation (CDE) to commence clinical trials of EVT 201.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com